Interim phase 2 data show INBRX-106 plus pembrolizumab nearly doubled response rates and extended survival vs pembrolizumab alone in head and neck cancer.
|Articles|June 20, 2016
ASCO 2016: Phase I Trial Results With Vorinostat in Head and Neck Cancer
Author(s)Theodoros Teknos, MD
In this interview, Theodoros Teknos, MD, discusses the results of his current phase I trial of vorinostat (Zolinza) in advanced head and neck cancer.
Advertisement
In this interview, Theodoros Teknos, MD, a Professor at The Ohio State University Medical School and Chairman for the Department of Otolaryngology (Head & Neck Surgery) at the Ohio State University Medical Center /James Cancer Hospital, sat down with the OncoTherapy Network to discuss the results of his current phase I trial of vorinostat (Zolinza) in advanced head and neck cancer.
These results were also presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 3-7, 2016, in Chicago (
Advertisement
Related to this article
Advertisement
Advertisement
Trending on CancerNetwork
1
IASO208 Receives FDA IND Clearance for Relapsed/Refractory B-Cell Lymphoma
2
Secondary T-Cell Malignancies: Identifying and Counseling After CAR T-Cell Therapy
3
SOHO 2026: Key Updates Across the Multiple Myeloma Continuum
4
FDA Approves sNDA for Taletrectinib in TKI-Naive Advanced ROS1+ NSCLC
5